Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 6,018 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at $1,913,300. This trade represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total value of $352,534.44.
• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52.

Enliven Therapeutics Stock Down 1.2%

ELVN traded down $0.58 during trading on Monday, hitting $48.87. 2,281,264 shares of the company traded hands, compared to its average volume of 1,268,609. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The stock’s fifty day moving average is $56.43 and its 200 day moving average is $46.17. The firm has a market cap of $3.58 billion, a P/E ratio of -29.26 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ELVN. BlackRock Inc. bought a new stake in shares of Enliven Therapeutics during the second quarter valued at about $221,255,000. First Light Asset Management LLC grew its stake in Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after acquiring an additional 1,158,883 shares in the last quarter. Siren L.L.C. purchased a new position in Enliven Therapeutics during the first quarter valued at approximately $29,252,000. Jupiter Topco LLC bought a new stake in Enliven Therapeutics during the 2nd quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $23,007,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ELVN shares. Guggenheim decreased their target price on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. HC Wainwright upped their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. The Goldman Sachs Group increased their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective for the company. Finally, Mizuho boosted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.